Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 744

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Identification of Targetable FGFR Gene Fusions in Diverse Cancers

Open access
Wu, Yi-Mi, Su, Fengyun, Kalyana-Sundaram, Shanker, Khazanov, Nickolay, Ateeq, Bushra, Cao, Xuhong, Lonigro, Robert J., Vats, Pankaj, Wang, Rui, Lin, Su-Fang, Cheng, Ann-Joy, Kunju, Lakshmi P., Siddiqui, Javed, Tomlins, Scott A., Wyngaard, Peter, Sadis, Seth, Roychowdhury, Sameek, Hussain, Maha H., Feng, Felix Y., Zalupski, Mark M., Talpaz, Moshe, Pienta, Kenneth J., Rhodes, Daniel R., Robinson, Dan R., Chinnaiyan, Arul M.·2013·Cancer Discovery
DOI 10.1158/2159-8290.cd-13-0050
Open this paper in CoChat — free account

Abstract

Through a prospective clinical sequencing program for advanced cancers, four index cases were identified which harbor gene rearrangements of FGFR2, including patients with cholangiocarcinoma, breast cancer, and prostate cancer. After extending our assessment of FGFR rearrangements across multiple tumor cohorts, we identified additional FGFR fusions with intact kinase domains in lung squamous cell cancer, bladder cancer, thyroid cancer, oral cancer, glioblastoma, and head and neck squamous cell cancer. All FGFR fusion partners tested exhibit oligomerization capability, suggesting a shared mode of kinase activation. Overexpression of FGFR fusion proteins induced cell proliferation. Two bladder cancer cell lines that harbor FGFR3 fusion proteins exhibited enhanced susceptibility to pharmacologic inhibition in vitro and in vivo. Because of the combinatorial possibilities of FGFR family fusion to a variety of oligomerization partners, clinical sequencing efforts, which incorporate transcriptome analysis for gene fusions, are poised to identify rare, targetable FGFR fusions across diverse cancer types. Significance: High-throughput sequencing technologies facilitate defining the mutational landscape of human cancers, which will lead to more precise treatment of patients with cancer. Here, through integrative sequencing efforts, we identified a variety of FGFR gene fusions in a spectrum of human cancers. FGFR fusions are active kinases. Cells harboring FGFR fusions showed enhanced sensitivity to the FGFR inhibitors PD173074 and pazopanib, suggesting that patients with cancer with FGFR fusions may benefit from targeted FGFR kinase inhibition. Cancer Discov; 3(6); 636–47. ©2013 AACR. See related commentary by Sabnis and Bivona, p. 607 This article is highlighted in the In This Issue feature, p. 591

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-13-0050

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 744

Metadata

Authors
Wu, Y.-M., Su, F., Kalyana-Sundaram, S., Khazanov, N., Ateeq, B., Cao, X., Lonigro, R. J., Vats, P., Wang, R., Lin, S.-F., Cheng, A.-J., Kunju, L. P., Siddiqui, J., Tomlins, S. A., Wyngaard, P., Sadis, S., Roychowdhury, S., Hussain, M. H., Feng, F. Y., Zalupski, M. M., Talpaz, M., Pienta, K. J., Rhodes, D. R., Robinson, D. R., & Chinnaiyan, A. M.
Venue
Cancer Discovery
Publisher
American Association for Cancer Research (AACR)
Published
2013-06-01
Volume
3
Issue
6
Pages
636-647
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
DOI
10.1158/2159-8290.cd-13-0050
OpenAlex
W2107977954
Cited by
744
References
43
FWCI
27.70
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of Targetable FGFR Gene Fusions in Diverse Cancers. https://app.cochat.ai/papers/10.1158/2159-8290.cd-13-0050
The paper
Wu, Y.-M., Su, F., Kalyana-Sundaram, S., Khazanov, N., Ateeq, B., Cao, X., Lonigro, R. J., Vats, P., Wang, R., Lin, S.-F., Cheng, A.-J., Kunju, L. P., Siddiqui, J., Tomlins, S. A., Wyngaard, P., Sadis, S., Roychowdhury, S., Hussain, M. H., Feng, F. Y., . . . Chinnaiyan, A. M. (2013). Identification of Targetable FGFR Gene Fusions in Diverse Cancers. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-13-0050

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.